[AMGN] Amgen Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 147.55 Change: 1.19 (0.81%)
Ext. hours: Change: 0 (0%)

chart AMGN

Refresh chart

Strongest Trends Summary For AMGN

AMGN is in the long-term up 382% in 16 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine worldwide. Its principal products include Neulasta, a pegylated protein for the treatment of chemotherapy-induced febrile neutropenia; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for treating the patients with non-myeloid malignancies; and Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis in adult patients. The company?s principal products also comprise Aranesp and EPOGEN erythropoiesis-stimulating agents for the treatment of anemia and dialysis; XGEVA and Prolia for the prevention of skeletal-related events and treatment of postmenopausal women with osteoporosis; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in CKD patients on dialysis. Its other marketed products include Nplate

Fundamental Ratios
Shares Outstanding EPS10.63 EPS Growth - 4 Quarters-5.54% EPS Growth - Q/Q23.37%
EPS Growth - Y/Y-9.79% Sales Growth - 4 Quarters -2.84% Sales Growth - Q/Q-5.59% P/E15.28
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA8.28% ROE21.53% ROI9.63%
Current Ratio5.53 Quick Ratio5.11 Long Term Debt/Equity1.04 Debt Ratio0.24
Gross Margin78.78% Operating Margin33.29% Net Profit Margin27.74% Dividend Payout Ratio-34.86%
Dividend Yield
Fundamental Data
Cash From Financing Activities-1.24 B Cash From Investing Activities-952 M Cash From Operating Activities1.33 B Gross Profit4.57 B
Net Profit1.65 B Operating Profit2.08 B Total Assets71.21 B Total Current Assets37.74 B
Total Current Liabilities6.89 B Total Debt31.95 B Total Liabilities43.73 B Total Revenue5.37 B
Technical Data
High 52 week206.65 Low 52 week165 Last close194.87 Last change5.95%
RSI76.37 Average true range5.08 Beta0.85 Volume2.05 M
Simple moving average 20 days8.76% Simple moving average 50 days8.94% Simple moving average 200 days5.51%
Performance Data
Performance Week4.82% Performance Month10.25% Performance Quart15.18% Performance Half5.58%
Performance Year0.68% Performance Year-to-date0.88% Volatility daily2% Volatility weekly4.47%
Volatility monthly9.16% Volatility yearly31.75% Relative Volume183.77% Average Volume2.88 M
New High New Low

News

2019-10-18 12:05:04 | Will Soliris Aid Growth for Alexion ALXN in Q3 Earnings?

2019-10-18 09:00:00 | Nplate® romiplostim Now Approved For Earlier Use In Adults With Immune Thrombocytopenia

2019-10-18 07:07:56 | The Daily Biotech Pulse: Intuitive Surgical Earnings, Paratek Pulls Out European Application For Antibiotic, Amgen's Evenity In Europe

2019-10-18 07:04:11 | Alexion to Buy Achillion for $930M, Strengthen PNH Franchise

2019-10-18 01:00:00 | EVENITY® Romosozumab Receives Positive CHMP Opinion For The Treatment Of Severe Osteoporosis In Postmenopausal Women At High Risk Of Fracture

2019-10-17 11:16:03 | Roche Posts Solid Sales for First 9 Months of '19, Ups View

2019-10-17 10:54:02 | Can New Drugs Help Lilly LLY to Deliver Solid Q3 Earnings?

2019-10-16 11:43:56 | Alexion makes $930M acquisition in bid to bolster blockbuster drug

2019-10-16 09:17:01 | Biogen BIIB to Report Q3 Earnings: What's in the Cards?

2019-10-15 17:45:09 | Amgen AMGN Gains But Lags Market: What You Should Know

2019-10-15 14:39:49 | Sanofi opens new Framingham site amid $1.6B bet on bio-manufacturing

2019-10-15 09:00:00 | Sports Anchor And Multiple Myeloma Patient Rod Gilmore Joins Amgen's Myeloma MVP™ Team

2019-10-14 10:14:02 | Lilly Gets FDA Approval for New Oral Tablets for Migraine

2019-10-14 09:28:01 | Roche Announces Positive Late-Stage Data on Rituxan in PV

2019-10-11 16:27:22 | Here Are Two Biotech Stocks To Watch As Earnings Season Kicks Off

2019-10-11 15:03:00 | These battered biotech stocks are now buying opportunities as Elizabeth Warren climbs in the polls

2019-10-11 12:29:04 | Top Research Reports for Toyota, Amgen & TJX

2019-10-11 09:27:01 | Alexion ALXN Collaborates With Stealth BioTherapeutics

2019-10-10 10:58:02 | 3 Big Drug/Biotech Stocks Set to Beat Q3 Earnings Estimates

2019-10-10 07:03:26 | Should You Be Worried About Insider Transactions At Amgen Inc. NASDAQ:AMGN?

2019-10-09 17:45:09 | Amgen AMGN Gains But Lags Market: What You Should Know

2019-10-09 16:46:03 | Is Amgen, Inc. AMGN A Good Stock To Buy According To Hedge Funds?

2019-10-09 09:04:00 | Amgen Foundation Launches Amgen Biotech Experience In Pittsburgh

2019-10-08 15:10:35 | Phillips 66 puts former Walmart CFO on board

2019-10-08 11:43:35 | UPDATE 2-Humira, Rituxan top list of U.S. drugs with biggest price increases -report

2019-10-08 09:18:01 | Why Alexion is a Hot Takeover Target in the Biotech Sector

2019-10-07 10:36:27 | Pfenex Gets FDA Seal of Approval For Amgen's Forteo Biosimilar

2019-10-07 09:30:01 | Has Amgen AMGN Outpaced Other Medical Stocks This Year?

2019-10-07 06:00:00 | After 500% Surge, Mirati’s Day of Reckoning Is Approaching

2019-10-04 16:29:42 | A Key Novartis Drug Could Be Delayed — Why This Stock Is Cheering

2019-10-04 09:30:57 | 3 Drug Stocks Poised for Gains After Cancer Conference

2019-10-03 17:45:09 | Amgen AMGN Outpaces Stock Market Gains: What You Should Know

2019-10-03 15:49:50 | Biotech Stock On The Radar: FDA Verdict Ahead For Pfenex's Osteoporosis Biosimilar

2019-10-03 11:22:03 | Merck's Pediatric Filings for Dificid Get FDA's Priority Review

2019-10-03 07:00:00 | Amgen, Merck and Others Highlighted Cancer-Drug Developments in Barcelona

2019-10-02 11:04:56 | Seeing the Baseline

2019-10-02 07:34:11 | Top Ranked Income Stocks to Buy for October 2nd

2019-10-01 09:10:01 | Should Value Investors Buy Amgen AMGN Stock?

2019-09-30 14:07:00 | Seattle Genetics, Merck, Bristol-Myers Unveil Upbeat Treatment Data at Cancer Conference

2019-09-28 10:59:17 | UPDATE 1-Targeted Amgen drug has low response rate in colon cancer in study

2019-09-28 01:30:00 | Low response rate reported for Amgen targeted drug in colon cancer trial

2019-09-28 01:00:00 | Amgen Announces New Clinical Data Evaluating Novel Investigational KRASG12C Inhibitor In Patients With Solid Tumors At ESMO 2019

2019-09-27 21:52:00 | Bye-bye, Biotech Funds? Not So Fast. It Could Be Time for Another Look

2019-09-27 17:50:09 | Amgen AMGN Stock Moves -0.23%: What You Should Know

2019-09-27 09:34:01 | Should First Trust Capital Strength ETF FTCS Be on Your Investing Radar?

2019-09-27 09:15:00 | ARWR: Broad-Based Pipeline Progress. Three Pivotal Studies, Value-Inflection Opportunities In View.

2019-09-26 16:55:08 | Cutting Rates 50 bps. Smart, Dumb, Not Enough?

2019-09-26 12:05:04 | Medicines Company's Inclisiran Succeeds in Pivotal Studies

2019-09-26 10:46:00 | A Big Cancer Conference Starts Tomorrow. Here’s What It Means for Merck, Bristol-Myers and Other Drug Stocks.

2019-09-26 09:02:01 | Incyte Treats First Patient in Phase III Vitiligo Study